



HAL
open science

Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma

Michael A. Fridrik, Hubert Hausmaninger, Alois Lang, Johannes Drach, Otto Krieger, Dietmar Geissler, Gerhard Michlmayr, Ernst Ulsperger, Andreas Chott, Wilhelm Oberaigner, et al.

► **To cite this version:**

Michael A. Fridrik, Hubert Hausmaninger, Alois Lang, Johannes Drach, Otto Krieger, et al.. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. *Annals of Hematology*, 2009, 89 (3), pp.273-282. 10.1007/s00277-009-0811-x . hal-00535085

HAL Id: hal-00535085

<https://hal.science/hal-00535085>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma

Michael A. Fridrik · Hubert Hausmaninger · Alois Lang · Johannes Drach · Otto Krieger · Dietmar Geissler · Gerhard Michlmayr · Ernst Ulsperger · Andreas Chott · Wilhelm Oberaigner · Richard Greil

Received: 1 June 2008 / Accepted: 5 August 2009 / Published online: 20 August 2009
© Springer-Verlag 2009

Abstract This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated aggressive lymphoma. One hundred and fifteen patients with untreated aggressive lymphoma were stratified by center, age, and international prognostic index and randomized to one of two treatment arms. One hundred and three were eligible. The experimental dose-dense arm consisted of weekly therapy with cyclophosphamide, epirubicin, vincristine, prednisolone, ifosfamide, etoposide, methotrexate, dexamethasone, and filgrastim

(CEOP/IMVP-Dexa). The standard arm consisted of three-weekly cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). The primary endpoint was overall survival after 3 years. Overall survival at 3 years was 0.766 (95% CI 0.6247, 0.8598) in the dose-dense arm and 0.462 (95% CI 0.3200, 0.5925) in the CHOP arm. Overall 5-year survival was 0.746 (95% CI 0.603, 0.843) in the dose dense and 0.406 (95% CI 0.265, 0.543) in the CHOP arm ($P=0.0062$). Grade 3 and 4 infections occurred four times more frequently in the dose-dense arm. However, two

Partly presented in the 39th Meeting of the American Society of Clinical Oncology, Chicago.

ClinicalTrials.gov registration no. NCT00517894

M. A. Fridrik (✉)
Department Internal Medicine 3, Centre for Hematology
and Medical Oncology, General Hospital Linz,
Krankenhausstrasse 9,
4020 Linz, Austria
e-mail: michael.fridrik@akh.linz.at

H. Hausmaninger · R. Greil
Department Medicine, University Salzburg,
Salzburg, Austria

A. Lang
Department Medicine LKH,
Feldkirch, Austria

J. Drach
Internal Department 1, University Vienna,
Vienna, Austria

O. Krieger
Department Internal Medicine 1, Kh-Elisabethinen,
Linz, Austria

D. Geissler
Department Medicine LKH,
Klagenfurt, Austria

G. Michlmayr
Department Medicine 1, Kh Bh Schwestern,
Linz, Austria

E. Ulsperger
Department Medicine Kh,
Lainz, Austria

A. Chott
Department Pathology, University Vienna,
Vienna, Austria

W. Oberaigner
Institute for Clinical Epidemiology of the TILAK,
Innsbruck, Austria

patients died from toxicity in the dose-dense arm and three in the CHOP arm. Dose-dense therapy with CEOP/IMVP-Dexa is feasible and resulted in an absolute increase of 34% in the survival probability compared to CHOP in untreated patients with aggressive lymphoma.

Keywords Aggressive non Hodgkin lymphoma · Treatment · Dose-dense · Diffuse large B-cell lymphoma

Introduction

The cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) polychemotherapy regimen was the first therapy to cure aggressive non-Hodgkin's lymphoma [7]. With this therapy, the overall survival of patients is 52% at short-term follow-up, but long-term remissions occur in less than 30% of patients [9, 17]. Therefore, more efficient therapies are urgently needed.

Several treatment regimens using more than four drugs, based on the Goldie–Coldman hypothesis [13] of using more effective drugs early in treatment to avoid resistance, improved survival when tested in single-center, phase II studies. However, in randomized trials, these regimens proved to be more toxic than CHOP [8]. Problems with patient selection may be the major reason why these newer regimens had inferior outcome in the randomized trial despite promising results in the phase II trials. Additionally, increasing the number of drugs in a treatment regimen usually results in a dose reduction of the key drugs cyclophosphamide and anthracycline. This may also explain the failure of these newer regimens.

The concept of dose density is the application of cytotoxic drugs in short intervals to target the malignant cells during the phase of rapid regrowth after the last treatment. The cyclophosphamide, epirubicine, vincristine, prednisolone, ifosfamide, etoposide, methotrexate, dexamethasone, and filgrastim (CEOP/IMVP-Dexa) is a dose-dense regimen, with weekly administration of cytotoxic drugs. The dose of anthracycline and cyclophosphamide was not reduced compared to CHOP. To avoid excessive myelotoxicity, we alternated myelotoxic and less myelotoxic drugs and used prophylactic filgrastim. The regimen proved to be safe and effective in earlier trials of the Austrian Working Party for Medical Tumor Therapy (AGMT) with an overall survival of 0.583 after 8 years [11]. In this study, we tested the hypothesis that dose-dense therapy results in better survival than CHOP in patients with untreated aggressive lymphoma.

Patients and methods

This study (NHL-5) was a prospective, multicenter, randomized phase III study of the AGMT. The study was

reviewed by the ethics committees at each participating institution and was performed according to the Declaration of Helsinki. Central randomization was done using a computer method; patients were stratified by center, international prognostic index (IPI) [1], and age. All patients gave written informed consent before entry.

The primary endpoint was survival after 3 years. The secondary endpoints were survival after 5 years, time to treatment failure after 3 and 5 years, remission rate, and toxicity.

Between February 1995 and September 2001, 115 patients were randomized. Patients between 18 and 70 years of age and with centrally reviewed, histologically confirmed diffuse large B cell, anaplastic large-cell lymphoma, or peripheral T cell lymphoma unspecified, measurable disease, in all stages, were included in the study. Patients with lymphoblastic or Burkitt histology, CNS disease, HIV-positive patients, pregnant or lactating women, pretreatment, other malignancy, or concomitant diseases that precluded chemotherapy were excluded from the study.


Treatment

The dose-dense therapy (CEOP/IMVP-Dexa) was provided as previously described [10, 12]. Briefly, cyclophosphamide (750 mg/m² i.v. day1), epirubicine (70 mg/m² i.v. day1), vincristine (1.4 mg/m² i.v. day1+8), prednisolone (100 mg p.o. days1–5), ifosfamide (2,000 mg/m² i.v. days15–17), etoposide (100 mg/m² i.v. days15–17), dexamethasone (40 mg p.o. or i.v. days15–19), and methotrexate (800 mg/m² i.v. day22) were used. Mesna uroprotection was given after ifosfamide and calcium folinate rescue after methotrexate. Filgrastim was given on days2–7, 9–12, 18–21, and 23–28. Chemotherapy doses were maintained unless neutrophil counts fell below 1.0 G/L. If neutrophil counts fell between 1.0 and 0.2 G/L, doses were reduced to 50%. If neutrophil counts were 0.2 G/L or lower, chemotherapy was delayed for 1 week. In patients with infections, chemotherapy was delayed until recovery. Antibiotic prophylaxis was not used. Patients 60 years of age or older had a 20% dose reduction for all cytostatic drugs.

In the experimental dose-dense arm, two to four cycles of CEOP/IMVP-Dexa was given to reach a complete remission (CR). Patients who did not achieve a partial remission (PR) after two cycles or a CR after four cycles were removed from the study and treated at the discretion of the treating physician. Patients achieving a CR received two consolidation cycles after achieving the CR (Fig. 1)

In the standard arm, three-weekly CHOP was given as described earlier [7]. Three to six cycles were given to reach a CR. Patients who did not reach a PR after three cycles or a CR after six cycles were removed from the

Fig. 1 Treatment plan




study and treated at the discretion of the treating physician. Patients achieving a CR received three consolidation cycles after achieving the CR (Fig. 1). The number of treatment cycles depended on how quickly the patient responded to the treatment. In patients with one to five cycles in the CHOP arm or one to three cycles in the dose-dense arm the treatment was stopped because of progression, toxicity, or early death (Figs. 1 and 2).

Biostatistics

All eligible patients were included in the analysis. Survival estimates were obtained by the Kaplan–Meier method [16]. The log-rank test was used to compare survival between the two arms. Unadjusted hazard ratios were estimated by the COX regression [6]. The patient characteristics, side effects, and remission rates were compared using the *t* test,

Fig. 2 Flow sheet of patients and number of cycles received



the parameter-free test, or the Pearson chi-square test, where appropriate.

To detect an estimated improvement in the 3-year survival from 0.54 to 0.72 with a power of 80% and an alpha-error of 0.05 in a one-sided test, at least 50 patients per study arm were required. We chose a one-sided test because we were only interested in determining if dose-dense therapy was better than CHOP.

CR, complete remission undetermined (CRu), PR, no change, progression, time to relapse, and time to treatment failure (TTF) were defined according to Cheson et al. [4]. Thus, survival includes all eligible patients and counts all deaths as events. TTF is the time from registration until relapse, progression, toxic death, withdrawal, or date last known to be alive, excluding deaths from unrelated causes.

Toxicity

Toxicity was assessed before each chemotherapy dose and whenever the patient visited the outpatient clinic using the WHO toxicity criteria (<http://www.fda.gov/cder/cancer/toxicityframe.htm>). Patients randomized to the dose-dense arm had weekly visits, while those in the CHOP arm were seen at 3-week intervals. In order to avoid differences resulting from the different evaluation intervals in the two arms, only the most severe toxicity during the whole therapy was considered.

Results

Patients

Between February 1995 and September 2001, 115 patients were enrolled; 52 were randomized into the dose-dense arm, and 51 were randomized into the CHOP arm. Seven patients were excluded from the dose-dense arm and five from the CHOP arm. Most of the exclusions were due to

histology. In the dose-dense arm, two patients were excluded because no data were received from the treatment center, and one was excluded due to CNS involvement at diagnosis (Fig. 2). The patient characteristics were comparable in both arms (Table 1). The median observation time for surviving patients was 62.5 months.

Survival and treatment after relapse

Dose-dense therapy was advantageous in terms of overall survival. Overall survival at 3 years was 0.766 (95% CI 0.6247, 0.8598) in the dose-dense arm and 0.462 (95% CI 0.3200, 0.5925) in the CHOP arm. Overall survival at 5 years was 0.746 (95% CI, 0.603, 0.843) in the dose-dense arm and 0.406 (95% CI, 0.265, 0.543) in the CHOP arm. This latter difference was statistically significant with a *P* value of 0.0062 (Fig. 3). The 5-year TTF was 0.5516 (95% CI 0.4060, 0.6752) in the dose-dense arm and 0.4119 (95% CI 0.2697–0.5486) in the CHOP arm (Fig. 4). This difference almost reached the level of statistical significance (*P*=0.0564). Five-year overall survival for patients with low or low–intermediate IPI was 0.8471 (95% CI 0.6908, 0.9283) in the dose-dense and 0.5364 (95% CI 0.3621, 0.6852) in the CHOP arm, respectively (Fig. 5). For patients with high or high–intermediate IPI, 5-year overall survival was 0.4167 (95% CI 0.1525, 0.6653) in the dose-dense arm and 0.0769 (95% CI 0.0048, 0.2920) in the CHOP arm. For the patients in the low or low–intermediate IPI risk group, this difference was statistically significant different with a *P* value of 0.0219 (Fig. 5).

In the CHOP arm, a few more T cell lymphomas, primarily anaplastic large-cell lymphoma, were included. This difference was not statistically significant (Table 1). Because T cell lymphomas have a less favorable outcome than B cell lymphomas, we also analyzed our data when T cell lymphomas were excluded, but the survival benefit remained. In the dose-dense arm, one of the two patients with peripheral T cell lymphoma and one of the two patients with anaplastic large-cell lymphoma relapsed and

Table 1 Patients characteristics

	Dose-dense arm	CHOP arm	<i>P</i> value
Male/female, <i>n</i> (%)	26 (50%)/26 (50%)	31/20	0.271
Age (median years)	47	46	0.092
Age (range years)	20–69	18–68	
Age>60 years	11 (21.2%)	9 (17.6%)	0.653
IPI low/l-i	28 (53.8%)/12 (23.1%)	24 (47.1%)/14 (27.5%)	0.909
IPI h-i/high	5 (9.6%)/7 (13.5%)	6 (11.8%)/7 (13.7%)	
DLBCL	46	38	
ALCL	2	6	0.2157
PTL-U	2	5	
Unclassified	2	2	




Fig. 3 Overall survival (log-rank test: $P=0.0062$) after 5 years $P=0.00034359$, after 6 years $P=0.0138098$, and after 7 years $P=0.211773823$

subsequently died. In the CHOP arm, three of the six patients with peripheral T cell lymphoma and three of the six patients with anaplastic large-cell lymphoma relapsed and subsequently died (Table 4). When analyzing the subgroups, the patient numbers get smaller and results are less robust. However, it seems to be unlikely that the small number patients that died from relapsed T cell lymphoma explains the survival benefit of the dose-dense therapy.

In the case of relapse, two patients in the dose-dense arm and five patients in the CHOP arm received stem-cell transplants. Rituximab was a part of the salvage treatment in two patients in the dose-dense arm and in one patient in the CHOP arm.

Response

The overall remission rate was 94.2% (49/52) and 86.3% (44/51) in the dose-dense and the CHOP arm, respectively. A CR was achieved in 39 (75%) patients and a CRu in four




Fig. 4 Time to treatment failure (log-rank test: $P=0.0564$)




Fig. 5 Overall survival according to IPI. *Low* low and low-intermediate IPI, *High* high and high-intermediate IPI. $P=0.0219$ for low-dose dense vs. low CHOP. $P=0.148$ for high-dose dense vs. high CHOP

(7.7%) patients in the dose-dense arm. In the CHOP arm, 37 (72.5%) patients had a CR and none had a CRu. Only two patients (3.8%) progressed during therapy in the dose-dense arm and seven (13.7%) in the CHOP arm. These differences did not reach statistical significance. One patient died in the dose-dense arm before an evaluation of the remission was possible.

Dose intensity

The planned and received chemotherapy doses for both arms are listed in Table 2. The planned dose intensity for vincristine and the anthracyclines were comparable in both arms. The cyclophosphamide dose was higher in the CHOP arm, but ifosfamide was added to the dose-dense arm to compensate. In addition, etoposide and methotrexate were given in the dose-dense arm. The received dose intensity was somewhat lower than the planned dose intensity in the dose-dense arm.

Toxicity

Dose-dense therapy produced significantly more toxicity than standard therapy. Table 3 lists the side effects that were significantly different between the two arms. Because the blood samples were taken at different intervals (at least weekly intervals in the dose-dense arm and at least three-weekly intervals in the CHOP arm), the most severe toxicity for each treatment cycle was documented. Laboratory-documented toxicity, particularly hematologic toxicity, was higher in the dose-dense arm. In the dose-dense arm, long-term peripheral neuropathy grades 1 and 2 were reported in three and two patients, respectively, lasting up to 3 years after the end of therapy. Myelodysplastic

Table 2 Planned dose intensity (DI) and percentage of received dose of planned dose

Drug	Planned DI, mg/m ² /day		Median received dose, % (95% CI)	
	Dose-dense arm	CHOP arm	Dose-dense arm	CHOP arm
Cyclophosphamide	26.79	35.710	83.03 (80.78–85.28)	94.59 (93.09–96.09)
Epirubicine/doxorubicin	2.50	2.380	82.52 (80.25–84.80)	95.21 (93.70–96.71)
Vincristine	0.10	0.095	60.60 (57.23–63.96)	92.06 (89.30–94.82)
Prednisone	3.57	4.760	81.29 (78.47–84.11)	96.66 (92.40–100.9)
Ifosfamide	214.29		80.49 (77.32–83.65)	
Etoposide	10.72		79.57 (76.30–82.84)	
Dexamethasone	7.14		79.05 (75.37–82.74)	
Methotrexate	28.57		73.64 (69.79–77.50)	

CI confidence intervals

syndromes or leukemias were not observed to date. Two deaths due to toxicity occurred in the dose-dense arm. One patient died in CR at home, 6 weeks after the last therapy, from liver failure of unknown cause. Another patient died from pneumonia without neutropenia, 3 months after the last chemotherapy. In the CHOP arm, we observed three deaths due to toxicity, one due to sepsis and another due to myocardial infarction while on treatment. One patient died in CR because of cachexia after treatment (Fig. 2). Dose-dense therapy with CEOP–IMVP–Dexa can be given as an outpatient regimen. However, most patients were hospitalized on days 15–17 and 22–24 of treatment. With this regimen, clinic visits on days 1, 8, 15–17, and 22–24 are necessary. CHOP regimen requires only one visit every 3 weeks. Although the cost of treatment was not an endpoint of our study, the more frequent clinic visits and larger number of drugs make the dose-dense therapy more costly than CHOP.

Treatment after relapse

Nineteen patients relapsed or progressed after a median of 64 weeks (range 9–217 weeks) in the dose-dense arm. Twelve of these 19 patients died of lymphoma after a median of 45 weeks (range 0–220 weeks) after relapse. Six patients are still alive after 137+ to 333+ weeks. Twenty-five patients relapsed or progressed after a median of 44 weeks (range 2–237 weeks) in the CHOP arm. All these patients died of lymphoma after a median of 45 weeks (range 2–214 weeks) after relapse. In the dose-dense arm, two patients received CEOP/IMVP as salvage treatment, three received CHOP, and 10 received other salvage chemotherapy regimens. Two were treated with a rituximab-containing regimen, and two received autologous stem-cell transplants. In the CHOP arm, three patients received salvage treatment with CEOP/IMVP, one with CHOP, and 19 with other regimens. One patient received

Table 3 Side effects: worst toxicity per patient according to WHO toxicity criteria listed as grade 0 (never had any toxicity), grade 3, and grade 4

Toxicity	Dose-dense arm			CHOP arm			<i>P</i>
	WHO grade 0 (%)	WHO grade 3 (%)	WHO grade 4 (%)	WHO grade 0 (%)	WHO grade 3 (%)	WHO grade 4 (%)	
Hemoglobin	0.0	39.2	7.8	56.0	4.0	2.0	<0.001
Neutrophil count	7.8	11.8	58.8	34.0	20.0	20.0	0.001
Platelet count	37.3	9.8	17.6	78.0	4.0	2.0	0.001
Stomatitis	13.7	27.5	2.0	66.0	0.0	0.0	<0.001
Nausea/vomiting	25.5	29.4	5.9	52.0	12.0	6.0	0.031
Fever	56.9	2.0	0.0	86.0	0.0	0	<0.001
Infection	9.8	25.5	7.8	50.0	6.0	2.0	<0.001
Hair loss	2.0	94.1	0.0	6.0	74.0	0.0	0.046
Skin	64.7	3.9	0.0	94.0	0.0	0.0	0.004
Neurotoxicity	13.7	11.8	3.9	56.0	4.0	0.0	<0.001

P Pearson chi-square test

Table 4 Outcome of relapsed patients

Patient no.	Randomization arm	Remission to 1st line therapy	Weeks from randomization to relapse	Weeks from relapse to death or last FU	Relapse therapy	Histology
18	CHOP	Prog	8	29	CEOP/IMVP	ALCL
105	CHOP	CR	51	36	CEOP/IMVP	PB
54	CHOP	PR	31	63	CEOP/IMVP	DLBCL
68	CHOP	CR	22	28	CHOP	PTCL
41	CHOP	CR	25	2	No treatment	DLBCL
103	CHOP	PR	27	32	R-salvage	DLBCL
32	CHOP	Prog	11	6	Salvage	DLBCL
55	CHOP	Prog	2	8	Salvage	DLBCL
114	CHOP	Prog	15	11	Salvage	DLBCL
24	CHOP	Prog	7	13	Salvage	DLBCL
75	CHOP	CR	27	15	Salvage	DLBCL
1	CHOP	PR	19	16	Salvage	DLBCL
65	CHOP	Prog	6	21	Salvage	DLBCL
76	CHOP	CR	63	23	Salvage	DLBCL
51	CHOP	PR	13	26	Salvage	PTCL
16	CHOP	CR	69	35	Salvage	DLBCL
115	CHOP	CR	33	93	Salvage	PTCL
21	CHOP	CR	90	95	Salvage	DLBCL
14	CHOP	PR	237	214	Salvage	DLBCL
84	CHOP	PR	39	16	Salvage+asct	DLBCL
111	CHOP	CR	41	35	Salvage+asct	DLBCL
106	CHOP	Prog	9	41	Salvage+asct	DLBCL
81	CHOP	CR	25	102	Salvage+asct	ALCL
19	CHOP	CR	207	134	Salvage+asct	DLBCL
60	CHOP	PR	19	32	Unknown	ALCL
59	Dose dense	CR	41	35	CEOP/IMVP	DLBCL
5	Dose dense	CR	217	333+	CEOP/IMVP	UNCLASS
13	Dose dense	CR	39	40	CHOP	DLBCL
6	Dose dense	CR+	85	220	CHOP	DLBCL
58	Dose dense	CR	59	323+	CHOP	DLBCL
99	Dose dense	PR	27	Lost	Lost	DLBCL
87	Dose dense	Prog	9	0	No treatment	DLBCL
88	Dose dense	PR	18	3	No treatment	DLBCL
113	Dose dense	CR+	61	105	other	PTCL
67	Dose dense	CR IF	213	137+	R-salvage	DLBCL
56	Dose dense	CR	197	192+	R-salvage+asct	DLBCL
3	Dose dense	CR+	29	2	Salvage	ALCL
104	Dose dense	PR	21	8	Salvage	DLBCL
27	Dose dense	CR	24	10	Salvage	DLBCL
35	Dose dense	PR	24	15	Salvage	DLBCL
91	Dose dense	CR	29	40	Salvage	DLBCL
71	Dose dense	PR	19	50	Salvage	DLBCL
100	Dose dense	CR	91	188+	Salvage	DLBCL
112	Dose dense	Prog	11	211+	Salvage+asct	DLBCL

R rituximab, *salvage* salvage chemotherapy other than CEOP/IMVP, *asct* autologous stem-cell transplantation, *DLBCL* diffuse large B cell lymphoma, *PB* plasmablastic lymphoma, *ALCL* anaplastic large-cell lymphoma, *PTCL* peripheral T cell lymphoma

rituximab-containing salvage therapy, and five patients had autologous stem-cell transplants (Table 4).

Discussion

In this randomized, multicenter trial, we tested whether dose-dense therapy improved survival over standard treatment with CHOP. We demonstrated that dose-dense therapy significantly improved the absolute survival by 30% after 3 years and 34% after 5 years (Fig. 3). Although survival is the most stable endpoint in clinical trials, some of our findings did not fit into the primary endpoint. The difference in the rate of remission and progression during therapy did not reach a statistically significant level. At the first glance, it is unclear how a better survival could be achieved without a difference in remissions. In the dose-dense arm, only three of six PRs relapsed. In the CHOP arm, all seven PRs relapsed (Table 4). The remissions were determined by CT scans, as PET scans were not generally available at the time of the study. Hence, we assume that the CR rate is misleading, and some of the PRs in the dose-dense arm were CRs. None of the two progressing patients died in the dose-dense arm, while all seven progressive patients died in the CHOP arm. TTF was better for the dose-dense arm, although this difference did not quite reach statistical significance. Stem-cell transplantation or ritux-

imab therapy, which are considered the most effective salvage treatments, do not explain this discrepancy since they were done in such low frequency (Table 4). The more likely explanation for the bigger difference in overall survival compared with TTF is that dose-dense therapy eradicates the most aggressive clones early on and relapses are easier to treat after dose-dense treatment. Unfortunately, we are not able to prove this assumption. However, from the patients' view, survival is the most important result; survival is the most reliable endpoint from the biostatisticians' view as well.

The sample size was thoroughly calculated to verify the difference between dose-dense and CHOP therapy, but it is small relative to other clinical trials. We tested CEOP/IMVP-Dexa in two previous AGMT trials (NHL-1 and NHL-3). The 3-year survivals in these trials were 0.7212 and 0.7610, respectively. These results support reproducibility of the 3-year survival of 0.766 in the recent trial. The survival in the CHOP arm is comparable with those in other trials (Table 5). However, in the German trial comparing CHOP14 with CHOP21, similar survival results were reported for the CHOP21 arm, despite an older population [22]. However, although the patients in our trial are positively selected regarding the age and IPI, comparisons between different trials must be interpreted with great caution because of unrecognized biases.

Table 5 Randomized trials with dose-dense regimens compared to CHOP

Author	Inclusion	Regimen	5-year EFS (%)	5-year OS (%)
Pfreundschuh [23]	<60a, IPI 0 or 1	CHOP14/21	58	80
		CHOEP14/21	69	84
Reyes [24]	<60a, IPI 0	CHOP	74	81
		ACVBP	82	90
Carde [3]	<70a, St III or IV	CHOP	26	28
		CHVmP-VB	43	48
Tilly [25]	60-69a, aaIPI>0	CHOP	29	39
		ACVBP	39	46
Pfreundschuh [22]	>60a	CHOP21	33	41
		CHOP14	44	53
Milpied [19]	<60a, aaIPI 1 or 2	CHOP	37	56
		CEEP+HDT	55	71
Linch [18]	<60a	CHOP	50	47
		PACEBOMB	60	56
Fridrik (NHL-5)	<71a	CHOP	41	40
		CEOP/IMVP	55	70

IPI international prognostic index, *aaIPI* age adjusted international prognostic index, *EFS* event-free survival, *CHOP* cyclophosphamide, doxorubicin, vincristine, prednisolone, *CHOEP* cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone, *ACVBP* doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisolone, *CHVmP-VB* cyclophosphamide, doxorubicin, VM-26, prednisolone, vincristine, bleomycin, *CEEP* cyclophosphamide, epirubicin, vindesine, prednisolone, *HDT* high-dose therapy, *CEOP/IMVP* cyclophosphamide, epirubicin, vincristine, prednisolone, ifosfamide, methotrexate, etoposide, *PACEBOMB* prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine, methotrexate

Another concern might be that the dose-dense regimen is an over treatment for low-risk patients. Subgroup analysis in trials with small patient numbers is always problematic. However, patients with low or low–intermediate IPI have a survival benefit with dose-dense therapy (Fig. 5).

A key question is whether patients in the dose-dense arm actually received more dose density than patients in the CHOP arm. The planned dose intensity was higher in the dose-dense arm than in the CHOP arm (Table 2). In addition, ifosfamide, etoposide, and methotrexate were given. On the other hand, dose reductions were more frequent in the dose-dense arm. For patients over the age of 60, a 20% dose reduction was mandatory. However, 45% of cycles of the dose-dense therapy were delayed for not more than 1 day, and in 85% of cycles, the therapy intervals were shorter than 3 weeks. Dose was adjusted to toxicity. Patients without toxicity received the full dose. In other patients, the dose was reduced to a tolerable level. Thus all patients received the highest tolerable dose density.

Toxicity is one of the major concerns in chemotherapy treatment regimens. Not surprisingly, the dose-dense arm had significantly higher toxicity (Table 3). However, most side effects subsided within a few weeks. Only neurotoxicity persisted up to 3 months after the dose-dense therapy. Myelodysplasia or leukemia was not observed. Treatment-related deaths were less frequent in the dose-dense arm. Apart from toxicity, dose-dense therapy is more cumbersome to apply, has higher costs, and requires more hospital or outpatients visits than CHOP. Considering the survival benefit of the dose-dense therapy, these disadvantages should be acceptable.

Other researchers have also shown that dose-dense regimens are more effective than CHOP. The superiority of ACVBP, a dose-dense regimen, was demonstrated for patients from 61 to 69 years of age 25 and at the least one adverse prognostic factor and for younger patients in stage I or II [24]. A British Group used PACEBOME in a dose-dense manner and had a superior cause-specific survival than CHOP [18]. Finally, bi-weekly CHOP showed better survival in an elderly population in a German trial [22]. In none of these trials did the difference with standard CHOP reach a level of 34% as it did in our study (Table 5). In a patient population similar to the population in our study, a 2-year overall survival of 67% was achieved with VACOP-B [2], a dose-dense regimen. However, VACOP-B has not been compared with CHOP in a randomized trial.

High-dose therapy with autologous stem-cell rescue was another promising attempt to overcome resistance and improve treatment outcome for aggressive non-Hodgkin's lymphoma. The results of this attempt were conflicting, and a recent comprehensive review of high-dose therapy in first-line treatment of aggressive non-Hodgkin's lymphoma failed to find an improvement [14]. The toxicity of high-

dose therapy prohibits subsequent cytotoxic therapy for a longer time period. If the high-dose therapy did not eradicate the last lymphoma cell, rapid regrowth of the lymphoma would take place, according to the Gompertzian model [20].

Rituximab (R) has considerably changed the treatment of B cell lymphoma [5, 15, 21, 23], but it was not available until after the recruitment for our study was completed. Chemotherapy without rituximab is no longer the standard treatment for diffuse large-cell lymphoma. Now, it is more important to determine if dose-dense therapy can improve on R-CHOP. The GELA Group is currently completing a randomized trial (LNH 03-6B) comparing R-CHOP21 to R-CHOP14. The results are eagerly awaited. The RICOVER60 trial could show that rituximab, when added to CHOP14, results in a better outcome [21]. We recently finished a phase II trial with dose-dense therapy and rituximab 375 mg/m² on days 1 and 15. Comparing these patients with the patients in this NHL-5 trial, we observed a significant TTF and OS benefit of R-CEOP/IMVP compared to CHOP. R-CEOP/IMVP also results in a better, but to date, not statistically significant TTF and OS compared to the dose-dense arm in NHL-5. If we will find a statistically significant difference with longer follow-up, we will conduct a randomized trial comparing R-CHOP with R-CEOP/IMVP. Until proven otherwise, R-CHOP still remains the standard.

Acknowledgments The study was supported by the Austrian social insurance company “Hauptverband österreichischer Sozialversicherungsträger”. This company provided the drugs used in the study.

References

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 329:987–994. doi:10.1056/NEJM199309303291402
2. Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Scalabrini DR, Salvi F, Todeschini G, Vitolo U, Resegotti L (1997) Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A=doxorubicin) vs VICOP-B (I=idarubicin). *Haematologica* 82:309–313
3. Carde P, Meerwaldt JH, van Glabbeke M, Somers R, Monconduit M, Thomas J, de Wolf-Peeters C, de Pauw B, Tanguy A, Kluin-Nelemans JC, Noordijk EM, Regnier R, Bron D, Lustinam-Marechal J, Caillou B, Bosq J, van Heerde P, van Unnik JAM, Burgers JMV, Hayat M, Cosset JM, Evd S, Wagener J, Hagenbeek A, Cattani A, Duez N, Tubiana M, on behalf of the ELG (1991) Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade Non-Hodgkin's Lymphoma (NHL): The 1980–1985 EORTC trial*. *Ann Oncol* 2:431–435
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris

- NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. *J Clin Oncol* 17:1244
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 346:235–242. doi:10.1056/NEJMoa011795
 6. Cox DL (1972) Regression models an life tables. *J Roy Statist Soc Ser B Methodological* 34:187
 7. DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease. *Lancet* 1:248–250. doi:10.1016/S0140-6736(75)91142-3
 8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med* 328:1002–1006. doi:10.1056/NEJM199304083281404
 9. Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA Jr (1987) Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. *Semin Hematol* 24:21–25
 10. Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stoger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T (1997) Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy *Ann Hematol* 75:135–140
 11. Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W (2005) Long-term results of dose density therapy in patients with aggressive lymphoma. *Ann Hematol* 84:217–222. doi:10.1007/s00277-004-0936-x
 12. Fridrik MA, Hausmaninger H, Linkesch W, Stoger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T (1996) CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. *J Clin Oncol* 14:227–232
 13. Goldie JH, Coldman AJ, Ng V, Hopkins HA, Looney WB (1988) A mathematical and computer-based model of alternating chemotherapy and radiation therapy in experimental neoplasms. *Antibiot Chemother* 41:11–20
 14. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluin-Nelemans HC, Martelli M, Milpied NJ, Santini G, Verdonck LF, Vitolo U, Schwarzer G, Engert A (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. *Cancer Treat Rev* 33:338–346. doi:10.1016/j.ctrv.2007.02.002
 15. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large b-cell lymphoma. *J Clin Oncol* 24:3121–3127
 16. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:547–581. doi:10.2307/2281868
 17. Kimby E, Brandt L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. *Acta Oncol* 40:198–212. doi:10.1080/02841860151116268
 18. Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, MacLennan KA, Vaughan B, Vaughan G, Gregory WM (2000) A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. *Ann Oncol* 11(Suppl 1):87–90. doi:10.1023/A:1008381811131
 19. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau J-L, the Groupe Ouest-Est des Leucemies et des Autres Maladies du S (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. *N Engl J Med* 350:1287–1295. doi:10.1056/NEJMoa031770
 20. Norton L, Simon R (1977) Growth curve of an experimental solid tumor following radiotherapy. *J Natl Cancer Inst* 58:1735–1741
 21. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol* 9:105–116. doi:10.1016/S1470-2045(08)70002-0
 22. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. *Blood* 104:634–641
 23. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT). *Group Lancet Oncol* 7:379–391. doi:10.1016/S1470-2045(06)70664-7
 24. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. *N Engl J Med* 352:1197–1205. doi:10.1056/NEJMoa042040
 25. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. *Blood* 102:4284–4289. doi:10.1182/blood-2003-02-0542